All News
Are TYK2 inhibitors ‘ticked’ to be part of the JAK family?
Are Tyk2 inhibitors JAK inhibitors?
Yes, no, maybe
Check out all of Dr. Janet Pope’s TYK2 Q&A.
https://t.co/IqeGqt6M4t https://t.co/kjWLVKVFP7
Links:
Dr. John Cush RheumNow ( View Tweet)
Differentiating AS from OCI using CT scanning by Terrier et al showed that Subchondral Bone Attenuation Coefficient (SBAC) was higher in OCI than AS with a threshold of >7500 Hounslow Units discriminating the two conditions #EULAR2022 @RheumNow POS0126 https://t.co/8MdSe3Dqp7
Dr. Antoni Chan synovialjoints ( View Tweet)
Measuring liver stiffness (LS) by transient elastography can detect and follow up hepatic involvement in AL amyloidosis as radiolabelled SAP scan not widely available by Brunger et al . Higher LS in with liver involvement vs heart/no involvement #EULAR2022 @RheumNow POS0124
Dr. Antoni Chan synovialjoints ( View Tweet)
GM-CSF increased in patients with active ankylosing spondylitis, correlates with disease activity, not duration. TNFi does not affect GM-CSF levels. Could explain efficacy of JAKinibs and response for residual inflammation during TNF blockade.
@RheumNow #EULAR2022 ABST#OP0107
Robert B Chao, MD doctorRBC ( View Tweet)
Depression was the most prevalent comorbidity (31%), hypertension (26%) and uveitis the most common EMM (30%) in AS from the PSOAS cohort by @rheum_cat .
Five clusters identified with depression and hypertension groups having higher disease activity #EULAR2022 @RheumNow OP0154 https://t.co/dpqaFD4Qzw
Dr. Antoni Chan synovialjoints ( View Tweet)
Check out my thoughts on this work on PMR's immunol signature:
video: https://t.co/7aTJMsR9Te
article: https://t.co/PTDHPv7gZC
for @RheumNow's #EULAR2022 coverage
PS just had a quick chat with @jiemy_william, so much exciting stuff to come from @VasculitisUMCG @ElisabethBrouw3! https://t.co/l94F5qAgDI
Links:
David Liew drdavidliew ( View Tweet)
#POS0716 #EULAR2022 Systematic review and meta-analysis of 7 studies (i.e. only 1 x proof of concept RCT) showed high SRI-4 response rate (82%) in #lupus patients treated on IL2. Injection reaction (33%) and Fever (24%). Promising and definitive RCT is needed @RheumNow https://t.co/BBcgt11yNT
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Congenital malformations after intra-uterine exposure to non-TNFi when compared to certolizumab showed vedolizumab and belimumab were associated with higher CMs. Vedolizumab showed specific CM pattern (corpus collosum agenesis).
@RheumNow #EULAR2022 ABST#OP0129 https://t.co/wgRlm9QLgW
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022
Ultrasound may be used to evaluate patients with RA (POS1393) and SSc (POS1394)
👁️Look for B-lines and pleural irregularity
Will require training of MSKUS rheumatologists, but another potential application of US in clinical practice
@RheumNow @MymaAlbaydaMD @USSONAR_Rh https://t.co/qtnBviKA3w
Eric Dein ericdeinmd ( View Tweet)
#POS0713 #EULAR2022 Exploratory analyses from Phase 2 RCT showed numerically more patients treated with BIIB059, a BDCA2 inhibitor achieved a clear (CLASI of 0-1) and almost clear cutaneous #lupus (CLASI 0-3). Looking forward to Phase 3 results in the next few years @RheumNow https://t.co/dDbwYCx7zT
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2022 annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Watch: EULAR 2022 - Day 1 Faculty Recap Pane
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.
https://t.co/OBLt7dOMa3 https://t.co/lHmEOIFIGa
Links:
Dr. John Cush RheumNow ( View Tweet)
No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest.
@RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
Robert B Chao, MD doctorRBC ( View Tweet)
“Post-exertional fatigue is real (in #LongCovid), not their fault. Validate their symptoms. Pain is secondary.”- Dr. @LCalabreseDO #EULAR2022 @rheumnow https://t.co/hDvxJfb14f
TheDaoIndex KDAO2011 ( View Tweet)
#POS0721 #EULAR2022 Are Aspirin + LMWH enough to prevent Adverse Pregnancy Outcomes (preterm, pregnancy loss, eclampsia) in High Risk Triple Antiphospholipid abs+ve + Low C3/C4? An Italian study of 128 patients said NO. Add Hydroxychloroquine @RheumNow https://t.co/927sZoHZEj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
JAKi for nonradiographic axSpA
One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. And the question of the utility of JAK inhibitors for the treatment of axSpA has been on the rise.
https://t.co/xq8ICyKKv0 https://t.co/o2iUgyU60A
Links:
Dr. John Cush RheumNow ( View Tweet)
Germano et al. Temporal artery abnormality on clinical exam predicts biopsy + . Arterial thickening and reduced pulse strongest predictors @RheumNow #EULAR2022 POS0820 https://t.co/Rs36ALSoJb
Richard Conway RichardPAConway ( View Tweet)
Merola et al. Risankizumab on MDA and DAPSA in KEEPsAKE 1 and 2. Week 24 MDA 25.0/25.6% vs 10.2/11.4%. DAPSA LDA+REM 41.2/36.8% week 24, 59.2/44.6% week 52 @RheumNow #EULAR2022 POS1029 https://t.co/Uz7kA76pMH
Richard Conway RichardPAConway ( View Tweet)
About 50% w/ #LongCOVID has persistent Sx's at 6 mos (fatigue, muscle weakness, insomnia, anxiety, depression, dyspnea). Risks: female, obesity &prior mechan ventilation. Interestingly, the pts have inc CRP levels. DLCO is low. – Prof R Mostard #EULAR2022 @rheumnow https://t.co/8jCEObjf5I
TheDaoIndex KDAO2011 ( View Tweet)
Risk factors associated with non-remission/LDA in PsA pts:
Baseline TJC>3, SJC>5
CRP>10
HAQ>0.5
enthesitis/dactylitis
BMI>30
sDMARD use
@RheumNow #EULAR2022 ABST#POS0080
Robert B Chao, MD doctorRBC ( View Tweet)